TSHA-102

About Taysha Gene Therapies

Taysha Gene Therapies is a publicly traded, clinical-stage biotechnology company singularly focused on eradicating monogenic diseases of the central nervous system. Founded in 2019, the company has rapidly advanced a pipeline of AAV9 gene therapies, with its lead candidate, TSHA-102, now in pivotal studies for Rett syndrome. Following a strategic restructuring in 2023 to extend its cash runway, Taysha's strategy centers on disciplined execution of its most promising clinical programs, supported by deep expertise from leaders who commercialized the first FDA-approved gene therapy for a monogenic CNS disorder.

About Abeona Therapeutics

Abeona Therapeutics has successfully transitioned to a commercial-stage company with the launch of ZEVASKYN®, while advancing a pipeline of novel gene therapies for rare diseases with high unmet need. Its strategy is built on a proprietary AIM™ vector platform designed for enhanced delivery and efficacy, and is vertically integrated with internal manufacturing capabilities. The company is focused on inherited retinal diseases and neurological disorders, with key partnered programs in Sanfilippo Syndrome and Rett Syndrome. Abeona's mission is to deliver transformative, one-time treatments, aiming to make cures the new standard of care.

Therapeutic Areas

Other Rett Syndrome Drugs